Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.To investigate molecular networks involved in immune response and other important biological processes
Subscribe to our email newsletter
NanoString Technologies (NanoString) is collaborating with the Broad Institute of MIT and Harvard, to investigate molecular networks involved in immune response and other important biological processes.
Reportedly, the three-year collaboration is also designed to explore ways to expand how NanoString’s next-generation digital gene expression technology can be applied to improve basic and clinical research.
As part of the collaboration, the Broad Institute is expected to use NanoString’s nCounter Analysis System to decipher entire networks of genes, to identify how these genes work together to carry out biological functions.
In addition, NanoString will design custom CodeSets (molecular barcodes associated with the genes of interest) based on gene signatures identified by Broad investigators. These gene sets may eventually be developed into commercially available assay panels for the nCounter system.
The current collaboration will expand and explore additional gene networks involved in innate and adaptive immunity, stem cell differentiation and non-coding RNA function, including the regulatory roles of the recently discovered long intervening non-coding RNAs (lincRNAs).
Eric Lander, director of the Broad Institute, said: “NanoString offers the ability to look at hundreds of genetic markers across many samples at relatively low cost and with high sensitivity. They have developed exciting technology with potential applications to a wide range of scientific problems. We look forward to working together to explore new ways of using of this technology.”
Wayne Burns, CEO of NanoString, said: “This wide-reaching collaboration with the Broad Institute provides further validation for the strength of the NanoString technology platform and its promise for enabling research studies that would otherwise be difficult or cost-prohibitive. One of the expected outcomes of this collaboration is to develop ways to make these types of molecular network analyses routine in studies of human disease.”